BioCentury | Mar 25, 2021
Regulation

March 24 Quick Takes: A first for Twist, Biotia and a refusal-to-file letter for Novo; plus Novartis’ radioligand, Zealand, four Japan approvals and more

...for a targeted therapy.With Zegalogue approval, Zealand preparing first U.S. launchFDA approved Zegalogue dasiglucagon from Zealand Pharma A/S...
...suspension, arikace, slit amikacin) 177Lu-PSMA-617, Lu177-PSMA-617 (PSMA-617, AAA617, [18F]PSMA-1007) Vitrakvi, larotrectinib (LOXO-101) Uplizna (inebilizumab, MEDI-551, MT-0551) Merck & Co. Inc. Zealand Pharma A/S Incyte...
BioCentury | Mar 23, 2020
Product Development

March 23 Quick Takes: Venclexta combo hits in AML; plus Jardiance rebuffed, Zolgensma approved in Japan and Zealand-Boehringer

...be available at that time. Zealand re-obtains amylin analog from Boehringer Boehringer has returned to Zealand Pharma A/S...
...ABT-199 (Compound #), GDC-0199 (Former compound #), venetoclax (Generic), Venclyxto (Other), Venclexta (Other) AbbVie Inc. Boehringer Ingelheim GmbH Zealand Pharma A/S Amylin...
BioCentury | Oct 23, 2019
Company News

Oct. 22 Company Quick Takes: Zealand acquires Encycle; plus Novartis, Vitalis, Roche-Spark

...Zealand expands peptide platform with Encycle acquisition Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will expand its peptide...
...U.S. Federal Trade Commission to complete their reviews of the deal. Hongjiang Li, Staff Writer Entresto, sacubitril/valsartan (LCZ696) Zealand Pharma A/S Encycle...
BioCentury | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

...see “Alexion Deal Lends Late-Stage Support to Stealth” ). Alexion partnered with Affibody AB and Zealand Pharma A/S...
BioCentury | Oct 11, 2019
Company News

Alexion deal lends late-stage support to Stealth

...Review that could Shorten Soliris’ Exclusivity” ). The company’s recent deals include a partnership with Zealand Pharma A/S...
BioCentury | Sep 6, 2019
Company News

Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more

...Parker as CEO, succeeding founding CEO Geoffroy de Ribains. Parker was EVP and CSO at Zealand Pharma A/S...
...CFO at Modus Therapeutics AB (Stockholm, Sweden) since April and previously served as CFO at Zealand Pharma...
BioCentury | Sep 5, 2019
Financial News

Sept. 5 Financial Quick Takes: Zealand raises cash as it readies NDA; plus Bellus, Aerie, LNC, Veralox and Sigrid

...Ahead of NDA submission, Zealand raising cash Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) is raising DKK559.6 million ($82.4 million...
...P2X ligand-gated ion channel 3 Paul Bonanos and Jonathan Block, Associate Editors Dasiglucagon (ZP4207) Aerie Pharmaceuticals Inc. Bellus Health Inc. Zealand Pharma A/S YSOPIA...
BioCentury | Aug 29, 2019
Company News

Management tracks: Reata, Scholar Rock, Vaccitech, Amunix, Azitra, Ortho Clinical

...The growth factor modulation company has begun a search for a successor. Peptide therapy company Zealand Pharma A/S...
BioCentury | Jul 29, 2019
Company News

July 29 Management tracks: Verastem names CEO; plus Zealand, Turning Point, Arvinas and more

...Lilly and Co. (NYSE:LLY) and has served as adviser to Verastem's commercial organization since May. Zealand Pharma A/S...
...day-to-day operations and clinical development, respectively, effective immediately. Jonathan Block, Associate Editor Arvinas Inc. Novaremed AG Protalix BioTherapeutics Inc. Verastem Inc. Zealand Pharma A/S Turning...
BioCentury | May 14, 2019
Clinical News

May 14 Clinical Quick Takes: Myovant, Solid, Minerva, Modus, Zealand

...the heparin analog. All endpoints met in Zealand's third Phase III trial for hypoglycemia candidate Zealand Pharma A/S...
...Lieu, Staff Writer Dasiglucagon (ZP4207) relugolix (TAK-385) seltorexant (JNJ-42847922, MIN-202) sevuparin (Sevuparin/DF02) SGT-001 Karolinska Development AB Minerva Neurosciences Inc. Modus Therapeutics AB Solid Biosciences Inc. Zealand Pharma A/S Myovant...
Items per page:
1 - 10 of 297
BioCentury | Mar 25, 2021
Regulation

March 24 Quick Takes: A first for Twist, Biotia and a refusal-to-file letter for Novo; plus Novartis’ radioligand, Zealand, four Japan approvals and more

...for a targeted therapy.With Zegalogue approval, Zealand preparing first U.S. launchFDA approved Zegalogue dasiglucagon from Zealand Pharma A/S...
...suspension, arikace, slit amikacin) 177Lu-PSMA-617, Lu177-PSMA-617 (PSMA-617, AAA617, [18F]PSMA-1007) Vitrakvi, larotrectinib (LOXO-101) Uplizna (inebilizumab, MEDI-551, MT-0551) Merck & Co. Inc. Zealand Pharma A/S Incyte...
BioCentury | Mar 23, 2020
Product Development

March 23 Quick Takes: Venclexta combo hits in AML; plus Jardiance rebuffed, Zolgensma approved in Japan and Zealand-Boehringer

...be available at that time. Zealand re-obtains amylin analog from Boehringer Boehringer has returned to Zealand Pharma A/S...
...ABT-199 (Compound #), GDC-0199 (Former compound #), venetoclax (Generic), Venclyxto (Other), Venclexta (Other) AbbVie Inc. Boehringer Ingelheim GmbH Zealand Pharma A/S Amylin...
BioCentury | Oct 23, 2019
Company News

Oct. 22 Company Quick Takes: Zealand acquires Encycle; plus Novartis, Vitalis, Roche-Spark

...Zealand expands peptide platform with Encycle acquisition Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will expand its peptide...
...U.S. Federal Trade Commission to complete their reviews of the deal. Hongjiang Li, Staff Writer Entresto, sacubitril/valsartan (LCZ696) Zealand Pharma A/S Encycle...
BioCentury | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

...see “Alexion Deal Lends Late-Stage Support to Stealth” ). Alexion partnered with Affibody AB and Zealand Pharma A/S...
BioCentury | Oct 11, 2019
Company News

Alexion deal lends late-stage support to Stealth

...Review that could Shorten Soliris’ Exclusivity” ). The company’s recent deals include a partnership with Zealand Pharma A/S...
BioCentury | Sep 6, 2019
Company News

Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more

...Parker as CEO, succeeding founding CEO Geoffroy de Ribains. Parker was EVP and CSO at Zealand Pharma A/S...
...CFO at Modus Therapeutics AB (Stockholm, Sweden) since April and previously served as CFO at Zealand Pharma...
BioCentury | Sep 5, 2019
Financial News

Sept. 5 Financial Quick Takes: Zealand raises cash as it readies NDA; plus Bellus, Aerie, LNC, Veralox and Sigrid

...Ahead of NDA submission, Zealand raising cash Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) is raising DKK559.6 million ($82.4 million...
...P2X ligand-gated ion channel 3 Paul Bonanos and Jonathan Block, Associate Editors Dasiglucagon (ZP4207) Aerie Pharmaceuticals Inc. Bellus Health Inc. Zealand Pharma A/S YSOPIA...
BioCentury | Aug 29, 2019
Company News

Management tracks: Reata, Scholar Rock, Vaccitech, Amunix, Azitra, Ortho Clinical

...The growth factor modulation company has begun a search for a successor. Peptide therapy company Zealand Pharma A/S...
BioCentury | Jul 29, 2019
Company News

July 29 Management tracks: Verastem names CEO; plus Zealand, Turning Point, Arvinas and more

...Lilly and Co. (NYSE:LLY) and has served as adviser to Verastem's commercial organization since May. Zealand Pharma A/S...
...day-to-day operations and clinical development, respectively, effective immediately. Jonathan Block, Associate Editor Arvinas Inc. Novaremed AG Protalix BioTherapeutics Inc. Verastem Inc. Zealand Pharma A/S Turning...
BioCentury | May 14, 2019
Clinical News

May 14 Clinical Quick Takes: Myovant, Solid, Minerva, Modus, Zealand

...the heparin analog. All endpoints met in Zealand's third Phase III trial for hypoglycemia candidate Zealand Pharma A/S...
...Lieu, Staff Writer Dasiglucagon (ZP4207) relugolix (TAK-385) seltorexant (JNJ-42847922, MIN-202) sevuparin (Sevuparin/DF02) SGT-001 Karolinska Development AB Minerva Neurosciences Inc. Modus Therapeutics AB Solid Biosciences Inc. Zealand Pharma A/S Myovant...
Items per page:
1 - 10 of 297